Cannabis and Ménière’s Disease: What the Evidence Actually Shows
Ménière’s disease causes recurrent vertigo, fluctuating hearing loss, tinnitus, and a sensation of pressure or fullness in the ear. Although the disorder’s underlying causes remain uncertain, its symptoms are associated with abnormal fluid regulation in the inner ear. Current treatment focuses on managing attacks and limiting their impact; there is no established cure.
Because cannabinoids influence neural signaling, pain, nausea, mood, and immune activity, researchers have investigated whether the endocannabinoid system might also play a role in hearing and balance. That line of research is scientifically plausible—but it has not yet established cannabis or cannabidiol (CBD) as a treatment for Ménière’s disease.
The endocannabinoid system includes naturally occurring signaling molecules such as anandamide and 2-arachidonoylglycerol, cannabinoid receptors including CB1 and CB2, and the enzymes that regulate these compounds. A 2008 study in rats detected CB2 receptors in the brainstem’s cochlear and vestibular nuclei, regions involved in hearing and balance. The finding suggests that cannabinoid signaling may contribute to auditory and vestibular function, but it does not show that activating those receptors treats disease in people.
The evidence involving tinnitus is similarly incomplete—and in some respects concerning. A review of the literature found that cannabinoids could theoretically affect the auditory pathways in either direction, with animal research raising the possibility that cannabinoid receptor activation might worsen tinnitus under some conditions. The review also noted that, at the time, no randomized human trials had tested cannabinoids as a tinnitus treatment. The authors of the review on cannabis and tinnitus concluded that the available evidence was insufficient to support therapeutic use.
Observational studies have not resolved the question. A 2020 analysis of U.S. adults reported an association between marijuana use and tinnitus after adjustment for several potential confounding factors. However, because the study was observational, it could not determine whether cannabis contributed to tinnitus, whether people with tinnitus were more likely to use cannabis, or whether another factor influenced both. A later study also reported an association between higher-volume cannabis use and tinnitus, but again did not establish causation.
Research on Ménière’s disease itself offers only indirect clues. A 2016 clinical study of 398 people with bilateral Ménière’s disease identified five patient subgroups based on features such as the timing of hearing loss, family history, migraine, and autoimmune disease. One subgroup was associated with migraine, while another involved autoimmune disease. These findings help illustrate the biological diversity of Ménière’s disease, but they did not evaluate cannabis, CBD, or cannabinoid treatment. The original study on clinical subgroups in bilateral Ménière’s disease therefore cannot be used as evidence that cannabinoids relieve the condition.
CBD has attracted attention because it is not intoxicating in the same way as THC and has shown anxiety-reducing effects in some laboratory and small human studies. A 2015 review of CBD and anxiety disorders found promising preclinical evidence and limited human evidence, particularly after single doses. The authors emphasized that chronic dosing, appropriate treatment doses, and effectiveness in relevant clinical populations remained insufficiently studied. Even if CBD helps anxiety related to Ménière’s disease, that would not necessarily mean it treats the inner-ear disorder or prevents vertigo, hearing loss, or tinnitus.
There is also a theoretical connection with nausea. In a small human parabolic-flight experiment, volunteers who developed motion sickness showed lower circulating endocannabinoid levels and reduced CB1 receptor expression than participants who did not become sick. The 2010 study suggested that endocannabinoid signaling may be involved in motion sickness, but it did not test cannabis as a treatment and did not study people with Ménière’s disease. Motion sickness and Ménière’s-related vertigo are not interchangeable conditions.
These distinctions are important. Evidence that cannabinoid receptors exist in auditory or vestibular pathways is mechanistic evidence, not proof of clinical benefit. Evidence that CBD may reduce anxiety does not establish an effect on Ménière’s disease. Evidence involving motion sickness does not demonstrate relief of inner-ear vertigo. Finally, associations between marijuana use and tinnitus do not prove that cannabis causes or treats tinnitus.
For now, cannabis and CBD should not be considered established treatments for Ménière’s disease. Products containing THC may cause dizziness, sedation, impaired coordination, anxiety, or changes in perception—effects that could complicate an already disabling balance disorder. CBD can also cause fatigue or sedation and may interact with medications. Product strength and purity may vary substantially outside regulated medical settings.
People with Ménière’s disease should discuss cannabis or CBD use with an otolaryngologist or other clinician, particularly if they take medications for vertigo, sleep, anxiety, pain, or blood pressure. The National Institute on Deafness and Other Communication Disorders’ treatment guidance describes established management approaches, including dietary and behavioral measures, medications for acute symptoms, vestibular rehabilitation, injections, and surgery in selected cases.
Further research may clarify whether specific cannabinoid compounds could eventually help with individual symptoms such as anxiety or nausea. Until controlled clinical trials directly evaluate cannabinoids in Ménière’s disease, however, the evidence supports further investigation—not a conclusion that marijuana is a proven therapeutic solution.
